3-(4-bromobutoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one | 1578300-98-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 3-(4-bromobutoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
• CAS: 1578300-98-7
• 化学式: C₁₇H₁₉BrO₃
• 分子量: 351.24
• InChiKey: FKSLTKAJALYEOI-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81 °C
• 沸点：
  510.2±50.0 °C(predicted)
• 密度：
  1.41±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.23
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  39.44
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-(4-bromobutoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one 、 6-氟-3-(哌啶-4-基)苯并[D]异恶唑 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 以68.1%的产率得到3-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)butoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
  参考文献：
  名称：

  Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics

  摘要：

  In this paper, we report the synthesis of novel, potential antipsychotic coumarin derivatives combining potent dopamine D-2, D-3 and serotonin 5-HT1A 5-HT(2)A receptors properties. We describe the structure activity relationship that leads us to the promising derivative: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin-1-yl)butoxy)-6-methyl-2,3-dihydrocyclopenta[c]chromen-4(1H)-one 27. The unique pharmacological features of compound 27 are a high affinity for dopamine D-2, D-3 and serotonin 5-HT1A, 5-HT2A receptors, together with a low affinity for H-1 receptor (to reduce the risk of obesity under chronic treatment). In animal models, compound 27 inhibited apomorphine-induced climbing and MK-801-induced hyperactivity without observable catalepsy at the highest dose tested. In particular, compound 27 was more potent than clozapine. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.012
• 作为产物：
  描述：

  庚二酸 在 aluminum (III) chloride 、 bismuth (III) nitrate pentahydrate 、 硫酸 、 potassium carbonate 、 三乙胺 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 生成 3-(4-bromobutoxy)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
  参考文献：
  名称：

  Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics

  摘要：

  In this paper, we report the synthesis of novel, potential antipsychotic coumarin derivatives combining potent dopamine D-2, D-3 and serotonin 5-HT1A 5-HT(2)A receptors properties. We describe the structure activity relationship that leads us to the promising derivative: 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl) piperidin-1-yl)butoxy)-6-methyl-2,3-dihydrocyclopenta[c]chromen-4(1H)-one 27. The unique pharmacological features of compound 27 are a high affinity for dopamine D-2, D-3 and serotonin 5-HT1A, 5-HT2A receptors, together with a low affinity for H-1 receptor (to reduce the risk of obesity under chronic treatment). In animal models, compound 27 inhibited apomorphine-induced climbing and MK-801-induced hyperactivity without observable catalepsy at the highest dose tested. In particular, compound 27 was more potent than clozapine. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.012

文献信息

• Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation
  作者：Qi He、Jing Liu、Jin-Shuai Lan、Jiaoli Ding、Yongbing Sun、Yuanying Fang、Neng Jiang、Zunhua Yang、Liyuan Sun、Yi Jin、Sai-Sai Xie

  DOI：10.1016/j.bioorg.2018.09.010

  日期：2018.12

  A series of new coumarin-dithiocarbamate hybrids were designed and synthesized as multitarget agents for the treatment of Alzheimer's disease. Most of them showed potent and clearly selective inhibition towards AChE and MAO-B. Among these compounds, compound 8f demonstrated the most potent inhibition to AChE with IC50 values of 0.0068 mu M and 0.0089 mu M for eeAChE and hAChE, respectively. Compound 8g was identified as the most potent inhibitor to hMAO-B, and it is also a good and balanced inhibitor to both hAChE and hMAO-B (0.114 mu M for hAChE; 0.101 mu M for hMAO-B). Kinetic and molecular modeling studies revealed that 8g was a dual binding site inhibitor for AChE and a competitive inhibitor for MAO-B. Further studies indicated that 8g could penetrate the BBB and exhibit no toxicity on SH-SY5Y neuroblastoma cells. More importantly, 8g did not display any acute toxicity in mice at doses up to 2500 mg/kg and could reverse the cognitive dysfunction of scopolamine-induced AD mice. Overall, these results highlighted 8g as a potential multitarget agent for AD treatment and offered a starting point for design of new multitarget AChE/MAO-B inhibitors based on dithiocarbamate scaffold.